Viking Therapeutics, Inc. (VKTX) Key Metrics
VKTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.20B
- Enterprise value
- $4.36B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 11.9 10-yr median 5.0
- EV / EBITDA
- — 10-yr median 42.6
- Dividend yield
- —
- Beta
- 0.65
VKTX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVKTX valuation Price multiples at each fiscal year-end price.
Price / book+24.4%
6.2
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−5.0 pts
−7.0%
2025 · hover or tap a bar for each year
20162025
VKTX returns How much profit the business earns on the capital it uses.
Return on equity−29.4 pts
−47.3%
2025 · hover or tap a bar for each year
20162025
Return on assets−27.1 pts
−44.3%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
VKTX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$3.19
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$2.47
2025 · hover or tap a bar for each year
20162025
Book value per share−29.7%
$5.67
2025 · hover or tap a bar for each year
20162025
Shares outstanding+3.3%
112.7M
2025 · hover or tap a bar for each year
20162025
VKTX financial health Debt, liquidity and how easily interest is covered.
Debt / equity−83.1%
0.00
2025 · hover or tap a bar for each year
20162025
Net debt+$195.9M
−$705.6M
2025 · hover or tap a bar for each year
20162025
Current ratio−71.8%
9.33
2025 · hover or tap a bar for each year
20162025
Debt / assets−84.5%
0.00
2025 · hover or tap a bar for each year
20162025
VKTX efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+17,565 days
26,703 days
2025 · hover or tap a bar for each year
20162025
VKTX valuation history
Fiscal year-endToday10-year median
VKTX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VKTX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VKTX cash returned to shareholders
DividendsBuybacksFree cash flow
VKTX price vs earnings per share
Share price at year-endEPS (right axis)
VKTX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.96B | $4.39B | $1.76B | $722.2M | $355.1M | $408.7M | $577.1M | $440.5M | $105.5M | — |
| Enterprise value | $3.26B | $3.49B | $1.39B | $568.3M | $153.0M | $160.7M | $302.1M | $139.0M | $88.3M | — |
| Price / book | 6.2 | 5.0 | 5.0 | 5.0 | 1.8 | 1.7 | 2.1 | 1.5 | 7.8 | — |
| EV / EBITDA | — | — | — | — | — | 42.6 | — | 29.8 | 199.5 | — |
| Earnings yield | −9.1% | −2.5% | −4.9% | −9.5% | −15.5% | −9.7% | −4.5% | −5.0% | −19.5% | — |
| Free cash flow yield | −7.0% | −2.0% | −4.2% | −6.7% | −13.4% | −5.3% | −4.3% | −4.3% | −14.0% | — |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | — | 1.0% | 0.4% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Share price at fiscal year-end | $35.18 | $40.24 | $18.61 | $9.40 | $4.60 | $5.63 | $8.02 | $7.65 | $4.06 | $1.19 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$3.19 | −$1.01 | −$0.91 | −$0.90 | −$0.71 | −$0.54 | −$0.36 | −$0.38 | −$0.79 | — |
| Operating cash flow per share | −$2.47 | −$0.81 | −$0.78 | −$0.63 | −$0.62 | −$0.30 | −$0.34 | −$0.33 | −$0.57 | — |
| Free cash flow per share | −$2.47 | −$0.81 | −$0.78 | −$0.63 | −$0.62 | −$0.30 | −$0.34 | −$0.33 | −$0.57 | — |
| Cash per share | $6.26 | $8.28 | $3.84 | $2.02 | $2.62 | $3.42 | $3.83 | $5.24 | $0.79 | — |
| Book value per share | $5.67 | $8.07 | $3.69 | $1.89 | $2.62 | $3.37 | $3.85 | $5.17 | $0.52 | — |
| Tangible book value per share | $5.67 | $8.07 | $3.69 | $1.89 | $2.62 | $3.37 | $3.85 | $5.17 | $0.52 | — |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Debt per share | $0.00 | $0.01 | $0.01 | $0.02 | $0.00 | $0.00 | $0.01 | — | $0.13 | — |
| Shares outstanding | 112.7M | 109.0M | 94.3M | 76.8M | 77.2M | 72.6M | 72.0M | 57.6M | 26.0M | — |
| Change in shares outstanding | +3.3% | +15.6% | +22.8% | −0.5% | +6.3% | +0.9% | +25.0% | +121.6% | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −47.3% | −17.9% | −34.8% | −39.7% | −24.6% | −15.1% | −9.0% | −14.2% | −191.4% | −175.7% |
| Return on assets (ROA) | −44.3% | −17.2% | −32.0% | −36.3% | −23.5% | −14.6% | −8.8% | −13.6% | −112.3% | −98.3% |
| Return on tangible assets | −50.2% | −12.1% | −23.3% | −40.9% | −26.1% | −15.4% | −9.1% | −7.3% | −93.0% | −101.3% |
| Financial health | ||||||||||
| Total debt | $137,000 | $1.1M | $1.3M | $1.6M | $29,000 | $359,000 | $662,000 | — | $3.5M | $3.3M |
| Cash & short-term investments | $705.7M | $902.6M | $362.1M | $155.5M | $202.1M | $248.4M | $275.6M | $301.5M | $20.6M | $13.2M |
| Net debt | −$705.6M | −$901.5M | −$360.8M | −$153.9M | −$202.1M | −$248.0M | −$275.0M | −$301.5M | −$17.1M | −$9.9M |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — | 0.26 | 0.41 |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — | 0.16 | 0.22 |
| Net debt / EBITDA | — | — | — | — | — | −65.82 | — | −64.70 | −38.67 | — |
| Current ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.11 | 41.83 | 66.40 | 2.52 | 2.16 |
| Quick ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.11 | 41.83 | 66.40 | 2.52 | 2.16 |
| Interest coverage | — | — | — | — | — | -402.5 | -223.9 | -46.5 | -9.8 | -6.8 |
| Working capital | $638.9M | $879.8M | $348.1M | $145.1M | $201.8M | $244.0M | $276.7M | $297.6M | $13.2M | $7.5M |
| Invested capital | −$66.5M | −$21.2M | −$12.4M | −$8.6M | −$190,000 | −$3.7M | $2.1M | −$3.8M | −$3.7M | −$1.8M |
| Tangible asset value | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M | $244.3M | $277.1M | $297.8M | $13.5M | $8.0M |
| Net current asset value | $638.9M | $879.2M | $347.2M | $143.8M | $201.8M | $243.9M | $276.4M | $297.6M | $13.2M | $7.5M |
| Graham net-net per share | $5.58 | $8.02 | $3.63 | $1.72 | $2.50 | $3.25 | $3.73 | $5.16 | $0.46 | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $22,288 |
| Share buybacks (net) | — | $42.1M | $7.1M | $6.8M | $707 | $296 | $151 | $127 | $22 | $229 |
| Capex / revenue | — | — | — | — | 0.0% | 0.0% | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | — | — | — | — | 57,004.0% | 54,216.8% | — | — | — | — |
| R&D / revenue | — | — | — | — | 420,343.9% | 297,558.5% | — | — | — | — |
| SG&A / revenue | — | — | — | — | 100,000.0% | 100,000.0% | — | — | — | — |
| Efficiency | ||||||||||
| Days payables outstanding | 26,703.4 | 9,138.2 | 10,025.6 | 6,254.5 | 3,349.1 | 4,229.1 | 2,379.5 | — | — | — |
| Payables turnover | 0.01 | 0.04 | 0.04 | 0.06 | 0.11 | 0.09 | 0.15 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $31.5M | $8.7M | $8.0M | $5.0M | $2.7M | $3.2M | $1.7M | $1.2M | $1.4M | $898,151 |
| Average inventory | — | — | — | — | — | — | — | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VKTX's annual financial statements (latest annual report filed February 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VKTX valuation and financial ratios
Viking Therapeutics earned a return on equity of −47.3% in fiscal 2025. It ended the year with $0.1 million of debt and $705.7 million in cash and short-term investments, a net cash position of $705.6 million.
See the VKTX income statement, the VKTX chart for price history, or the VKTX stock overview for the latest quote and news.
VKTX key metrics FAQ
What is Viking Therapeutics's return on equity?
Viking Therapeutics's return on equity (ROE) was −47.3% in fiscal 2025: net income of -$359.6 million on average shareholders' equity of $759.7 million.
How much debt does Viking Therapeutics have?
Viking Therapeutics had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Viking Therapeutics's free cash flow yield?
Viking Therapeutics generated -$278.7 million of free cash flow in fiscal 2025, a free cash flow yield of −7.0% on its market value at year-end ($4.0 billion).
What is Viking Therapeutics's current ratio?
Viking Therapeutics's current ratio was 9.33 at the end of fiscal 2025: current assets were 9.33 times current liabilities.